



COLONY STIMULATING FACTORS PRIOR AUTHORIZATION FORM

Prior authorization guidelines for Colony Stimulating Factors and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at <https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.html>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

CLINICAL INFORMATION

Drug requested:		Strength:	Dosage form (e.g., vial, syringe, kit, etc.):	
Dose/route/frequency:			Quantity:	Refills:
Diagnosis (<u>submit documentation</u>):			Dx code (required):	
Beneficiary's height: _____ ins / cms	Beneficiary's weight: _____ lbs / kg		BSA (<i>Leukine only</i>): _____ m ²	

Complete the sections below that are applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.

- Has recent results of a CBC with differential
- Is or will be receiving chemotherapy
- Is or will be receiving radiation therapy:

Dates or planned dates of radiation: _____

For a NON-PREFERRED Colony Stimulating Factor (CSF):

- Has a history of trial and failure of or a contraindication or an intolerance to the preferred Colony Stimulating Factors that are approved or medically accepted for treatment of the beneficiary's diagnosis (*Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.*)

Prophylaxis of chemotherapy-induced febrile neutropenia:

- Has at least 1 of the following risk factors for the development of febrile neutropenia:
 - Age >65 years
 - Recent surgery
 - History of febrile neutropenia
 - Poor liver or kidney function
 - Current infection or open wound
 - Previous chemotherapy or radiation
 - Cardiovascular disease



Poor nutritional or performance status

other: _____

Receiving or will receive a chemotherapy regimen with an expected incidence of neutropenia >20%

For pegfilgrastim (Neulasta, Udenyca, etc.):

Last date of chemo: _____

Planned administration date: _____

Next expected chemo date: _____

Treatment of febrile neutropenia:

Received or is receiving myelosuppressive anticancer drugs associated with neutropenia

Is at high risk for infection-related complications

Bone marrow transplant:

Has a non-myeloid malignancy and is undergoing myeloablative chemotherapy to be followed by bone marrow transplant

Planned transplant date: _____

Has non-Hodgkin's lymphoma, acute lymphoblastic leukemia, or Hodgkin's lymphoma and had an autologous bone marrow transplant

Transplant date: _____

Stem cell transplant:

Is planned for autologous peripheral stem cell transplant

Is planned for allogeneic peripheral stem cell transplant

Will be using the requested medication in combination with plerixafor (*also complete Mozobil prior authorization form*) or another stem cell mobilizer

Planned leukapheresis date: _____

Planned transplant date: _____

Had an autologous or allogeneic peripheral stem cell transplant

Transplant date: _____

Acute myeloid leukemia:

CSF will be used following induction chemotherapy

CSF will be used following consolidation chemotherapy

other: _____

Hematopoietic syndrome of acute radiation syndrome:

Suspected or confirmed exposure to a radiation dose >2 gray (Gy)

Severe chronic neutropenia – specify type: congenital neutropenia cyclic neutropenia idiopathic neutropenia

Experiencing symptoms of neutropenia

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.